A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Clinical trial NCT04534205 · RECRUITING

Trial details

NCT number: NCT04534205
Sponsor: BioNTech SE
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Unresectable Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer

Start date: 2021-01-07
Primary completion: 2029-04-01
Enrollment: 350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.